Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ VIPR1 Polyclonal Antibody

Goat Polyclonal Antibody
Supplier: Invitrogen™ PA5142782
This item is not returnable.
View return policy
Description
This antibody is tested in Peptide ELISA: antibody detection limit dilution 1:1,000.
The Vasoactive Intestinal Polypeptide Receptor 1 (VPAC1) is a member of a family of three G-protein coupled receptors which mediate VIP (vasoactive intestinal peptide) and PACAP (pituitary adenlyate cyclase activating peptide) function in a variety of tissues. Together, the VPAC1 and VPAC2 receptors compose a subtype of the VIP receptor. Expression of the VIP and PACAP receptors has been linked to the presence of human tumors.
Specifications
| VIPR1 | |
| Polyclonal | |
| Unconjugated | |
| VIPR1 | |
| AV071699; HVR1; II; Pacap receptor; PACAP type II receptor; PACAP-R2; PACAP-R-2; pituitary adenylate cyclase activating polypeptide receptor, type II; pituitary adenylate cyclase-activating polypeptide type II receptor; Pvr2; RATVASREC; RDC1; type 1 vasoactive intestinal peptide receptor; V1RG; VAPC1; vasoactive intestinal peptide receptor 1; vasoactive intestinal polypeptide receptor 1; Vasopressive intestinal peptide receptor; VASREC; VIP and PACAP receptor 1; VIP receptor 1; VIP receptor subtype 1; VIP receptor, type I; VIP1 receptor; VIPR; Vipr1; VIP-R1; VIP-R-1; VIRG; VPAC1; VPAC1 receptor; VPAC1R; VPCAP1R | |
| Goat | |
| Ammonium sulfate precipitation | |
| RUO | |
| 22354, 24875 | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Liquid |
| Western Blot | |
| 0.5 mg/mL | |
| TBS with 0.5% BSA and 0.02% sodium azide; pH 7.3 | |
| P30083, P97751 | |
| VIPR1 | |
| Peptide with sequence C-QLFSPIHGYNISRN. | |
| 100 μg | |
| Primary | |
| Mouse, Rat | |
| Antibody | |
| IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction